Brian L Furman. Toxicon 2012
Times Cited: 84
Times Cited: 84
Times Cited
Times Co-cited
Similarity
Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.
J Eng, W A Kleinman, L Singh, G Singh, J P Raufman. J Biol Chem 1992
J Eng, W A Kleinman, L Singh, G Singh, J P Raufman. J Biol Chem 1992
21
Venoms as a platform for human drugs: translating toxins into therapeutics.
Glenn F King. Expert Opin Biol Ther 2011
Glenn F King. Expert Opin Biol Ther 2011
16
Ziconotide: neuronal calcium channel blocker for treating severe chronic pain.
G P Miljanich. Curr Med Chem 2004
G P Miljanich. Curr Med Chem 2004
16
15
13
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
Daniel J Drucker, John B Buse, Kristin Taylor, David M Kendall, Michael Trautmann, Dongliang Zhuang, Lisa Porter. Lancet 2008
Daniel J Drucker, John B Buse, Kristin Taylor, David M Kendall, Michael Trautmann, Dongliang Zhuang, Lisa Porter. Lancet 2008
11
Peptide therapeutics from venom: Current status and potential.
Michael W Pennington, Andrzej Czerwinski, Raymond S Norton. Bioorg Med Chem 2018
Michael W Pennington, Andrzej Czerwinski, Raymond S Norton. Bioorg Med Chem 2018
10
Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
R Göke, H C Fehmann, T Linn, H Schmidt, M Krause, J Eng, B Göke. J Biol Chem 1993
R Göke, H C Fehmann, T Linn, H Schmidt, M Krause, J Eng, B Göke. J Biol Chem 1993
9
The toxicogenomic multiverse: convergent recruitment of proteins into animal venoms.
Bryan G Fry, Kim Roelants, Donald E Champagne, Holger Scheib, Joel D A Tyndall, Glenn F King, Timo J Nevalainen, Janette A Norman, Richard J Lewis, Raymond S Norton,[...]. Annu Rev Genomics Hum Genet 2009
Bryan G Fry, Kim Roelants, Donald E Champagne, Holger Scheib, Joel D A Tyndall, Glenn F King, Timo J Nevalainen, Janette A Norman, Richard J Lewis, Raymond S Norton,[...]. Annu Rev Genomics Hum Genet 2009
9
Complex cocktails: the evolutionary novelty of venoms.
Nicholas R Casewell, Wolfgang Wüster, Freek J Vonk, Robert A Harrison, Bryan G Fry. Trends Ecol Evol 2013
Nicholas R Casewell, Wolfgang Wüster, Freek J Vonk, Robert A Harrison, Bryan G Fry. Trends Ecol Evol 2013
9
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
9
From snake venom toxins to therapeutics--cardiovascular examples.
Cho Yeow Koh, R Manjunatha Kini. Toxicon 2012
Cho Yeow Koh, R Manjunatha Kini. Toxicon 2012
9
Contulakin-G, an O-glycosylated invertebrate neurotensin.
A G Craig, T Norberg, D Griffin, C Hoeger, M Akhtar, K Schmidt, W Low, J Dykert, E Richelson, V Navarro,[...]. J Biol Chem 1999
A G Craig, T Norberg, D Griffin, C Hoeger, M Akhtar, K Schmidt, W Low, J Dykert, E Richelson, V Navarro,[...]. J Biol Chem 1999
8
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
Jesper Lau, Paw Bloch, Lauge Schäffer, Ingrid Pettersson, Jane Spetzler, Jacob Kofoed, Kjeld Madsen, Lotte Bjerre Knudsen, James McGuire, Dorte Bjerre Steensgaard,[...]. J Med Chem 2015
Jesper Lau, Paw Bloch, Lauge Schäffer, Ingrid Pettersson, Jane Spetzler, Jacob Kofoed, Kjeld Madsen, Lotte Bjerre Knudsen, James McGuire, Dorte Bjerre Steensgaard,[...]. J Med Chem 2015
8
Potent neuroprotection after stroke afforded by a double-knot spider-venom peptide that inhibits acid-sensing ion channel 1a.
Irène R Chassagnon, Claudia A McCarthy, Yanni K-Y Chin, Sandy S Pineda, Angelo Keramidas, Mehdi Mobli, Vi Pham, T Michael De Silva, Joseph W Lynch, Robert E Widdop,[...]. Proc Natl Acad Sci U S A 2017
Irène R Chassagnon, Claudia A McCarthy, Yanni K-Y Chin, Sandy S Pineda, Angelo Keramidas, Mehdi Mobli, Vi Pham, T Michael De Silva, Joseph W Lynch, Robert E Widdop,[...]. Proc Natl Acad Sci U S A 2017
8
Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
Loretta L Nielsen, Andrew A Young, David G Parkes. Regul Pept 2004
Loretta L Nielsen, Andrew A Young, David G Parkes. Regul Pept 2004
7
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
John B Buse, Robert R Henry, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2004
John B Buse, Robert R Henry, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2004
7
Black mamba venom peptides target acid-sensing ion channels to abolish pain.
Sylvie Diochot, Anne Baron, Miguel Salinas, Dominique Douguet, Sabine Scarzello, Anne-Sophie Dabert-Gay, Delphine Debayle, Valérie Friend, Abdelkrim Alloui, Michel Lazdunski,[...]. Nature 2012
Sylvie Diochot, Anne Baron, Miguel Salinas, Dominique Douguet, Sabine Scarzello, Anne-Sophie Dabert-Gay, Delphine Debayle, Valérie Friend, Abdelkrim Alloui, Michel Lazdunski,[...]. Nature 2012
7
Non-enzymatic proteins from snake venoms: a gold mine of pharmacological tools and drug leads.
Ryan J R McCleary, R Manjunatha Kini. Toxicon 2013
Ryan J R McCleary, R Manjunatha Kini. Toxicon 2013
7
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
John B Buse, Michael Nauck, Thomas Forst, Wayne H-H Sheu, Sylvia K Shenouda, Cory R Heilmann, Byron J Hoogwerf, Aijun Gao, Marilyn K Boardman, Mark Fineman,[...]. Lancet 2013
John B Buse, Michael Nauck, Thomas Forst, Wayne H-H Sheu, Sylvia K Shenouda, Cory R Heilmann, Byron J Hoogwerf, Aijun Gao, Marilyn K Boardman, Mark Fineman,[...]. Lancet 2013
7
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Kathleen M Dungan, Santiago Tofé Povedano, Thomas Forst, José G González González, Charles Atisso, Whitney Sealls, Jessie L Fahrbach. Lancet 2014
Kathleen M Dungan, Santiago Tofé Povedano, Thomas Forst, José G González González, Charles Atisso, Whitney Sealls, Jessie L Fahrbach. Lancet 2014
7
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
Dennis Kim, Leigh MacConell, Dongliang Zhuang, Prajakti A Kothare, Michael Trautmann, Mark Fineman, Kristin Taylor. Diabetes Care 2007
Dennis Kim, Leigh MacConell, Dongliang Zhuang, Prajakti A Kothare, Michael Trautmann, Mark Fineman, Kristin Taylor. Diabetes Care 2007
7
Specialized insulin is used for chemical warfare by fish-hunting cone snails.
Helena Safavi-Hemami, Joanna Gajewiak, Santhosh Karanth, Samuel D Robinson, Beatrix Ueberheide, Adam D Douglass, Amnon Schlegel, Julita S Imperial, Maren Watkins, Pradip K Bandyopadhyay,[...]. Proc Natl Acad Sci U S A 2015
Helena Safavi-Hemami, Joanna Gajewiak, Santhosh Karanth, Samuel D Robinson, Beatrix Ueberheide, Adam D Douglass, Amnon Schlegel, Julita S Imperial, Maren Watkins, Pradip K Bandyopadhyay,[...]. Proc Natl Acad Sci U S A 2015
7
A role for glucagon-like peptide-1 in the central regulation of feeding.
M D Turton, D O'Shea, I Gunn, S A Beak, C M Edwards, K Meeran, S J Choi, G M Taylor, M M Heath, P D Lambert,[...]. Nature 1996
M D Turton, D O'Shea, I Gunn, S A Beak, C M Edwards, K Meeran, S J Choi, G M Taylor, M M Heath, P D Lambert,[...]. Nature 1996
5
Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4.
A Thum, K Hupe-Sodmann, R Göke, K Voigt, B Göke, G P McGregor. Exp Clin Endocrinol Diabetes 2002
A Thum, K Hupe-Sodmann, R Göke, K Voigt, B Göke, G P McGregor. Exp Clin Endocrinol Diabetes 2002
10
Early evolution of the venom system in lizards and snakes.
Bryan G Fry, Nicolas Vidal, Janette A Norman, Freek J Vonk, Holger Scheib, S F Ryan Ramjan, Sanjaya Kuruppu, Kim Fung, S Blair Hedges, Michael K Richardson,[...]. Nature 2006
Bryan G Fry, Nicolas Vidal, Janette A Norman, Freek J Vonk, Holger Scheib, S F Ryan Ramjan, Sanjaya Kuruppu, Kim Fung, S Blair Hedges, Michael K Richardson,[...]. Nature 2006
5
Peptide neurotoxins from fish-hunting cone snails.
B M Olivera, W R Gray, R Zeikus, J M McIntosh, J Varga, J Rivier, V de Santos, L J Cruz. Science 1985
B M Olivera, W R Gray, R Zeikus, J M McIntosh, J Varga, J Rivier, V de Santos, L J Cruz. Science 1985
5
Orthosteric binding of ρ-Da1a, a natural peptide of snake venom interacting selectively with the α1A-adrenoceptor.
Arhamatoulaye Maïga, Jon Merlin, Elodie Marcon, Céline Rouget, Maud Larregola, Bernard Gilquin, Carole Fruchart-Gaillard, Evelyne Lajeunesse, Charles Marchetti, Alain Lorphelin,[...]. PLoS One 2013
Arhamatoulaye Maïga, Jon Merlin, Elodie Marcon, Céline Rouget, Maud Larregola, Bernard Gilquin, Carole Fruchart-Gaillard, Evelyne Lajeunesse, Charles Marchetti, Alain Lorphelin,[...]. PLoS One 2013
62
Identification, structural and pharmacological characterization of τ-CnVA, a conopeptide that selectively interacts with somatostatin sst3 receptor.
C Petrel, H G Hocking, M Reynaud, G Upert, Ph Favreau, D Biass, M Paolini-Bertrand, S Peigneur, J Tytgat, N Gilles,[...]. Biochem Pharmacol 2013
C Petrel, H G Hocking, M Reynaud, G Upert, Ph Favreau, D Biass, M Paolini-Bertrand, S Peigneur, J Tytgat, N Gilles,[...]. Biochem Pharmacol 2013
19
Structure, function and evolution of three-finger toxins: mini proteins with multiple targets.
R Manjunatha Kini, Robin Doley. Toxicon 2010
R Manjunatha Kini, Robin Doley. Toxicon 2010
5
Conopressin-T from Conus tulipa reveals an antagonist switch in vasopressin-like peptides.
Sébastien Dutertre, Daniel Croker, Norelle L Daly, Asa Andersson, Markus Muttenthaler, Natalie G Lumsden, David J Craik, Paul F Alewood, Gilles Guillon, Richard J Lewis. J Biol Chem 2008
Sébastien Dutertre, Daniel Croker, Norelle L Daly, Asa Andersson, Markus Muttenthaler, Natalie G Lumsden, David J Craik, Paul F Alewood, Gilles Guillon, Richard J Lewis. J Biol Chem 2008
8
History of the design of captopril and related inhibitors of angiotensin converting enzyme.
D W Cushman, M A Ondetti. Hypertension 1991
D W Cushman, M A Ondetti. Hypertension 1991
5
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
David M Kendall, Matthew C Riddle, Julio Rosenstock, Dongliang Zhuang, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
David M Kendall, Matthew C Riddle, Julio Rosenstock, Dongliang Zhuang, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
5
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Michael Nauck, Anders Frid, Kjeld Hermansen, Nalini S Shah, Tsvetalina Tankova, Ismail H Mitha, Milan Zdravkovic, Maria Düring, David R Matthews. Diabetes Care 2009
Michael Nauck, Anders Frid, Kjeld Hermansen, Nalini S Shah, Tsvetalina Tankova, Ismail H Mitha, Milan Zdravkovic, Maria Düring, David R Matthews. Diabetes Care 2009
5
DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Thomas Blevins, John Pullman, Jaret Malloy, Ping Yan, Kristin Taylor, Christine Schulteis, Michael Trautmann, Lisa Porter. J Clin Endocrinol Metab 2011
Thomas Blevins, John Pullman, Jaret Malloy, Ping Yan, Kristin Taylor, Christine Schulteis, Michael Trautmann, Lisa Porter. J Clin Endocrinol Metab 2011
5
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
Alan Garber, Robert Henry, Robert Ratner, Pedro A Garcia-Hernandez, Hiromi Rodriguez-Pattzi, Israel Olvera-Alvarez, Paula M Hale, Milan Zdravkovic, Bruce Bode. Lancet 2009
Alan Garber, Robert Henry, Robert Ratner, Pedro A Garcia-Hernandez, Hiromi Rodriguez-Pattzi, Israel Olvera-Alvarez, Paula M Hale, Milan Zdravkovic, Bruce Bode. Lancet 2009
5
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).
M Marre, J Shaw, M Brändle, W M W Bebakar, N A Kamaruddin, J Strand, M Zdravkovic, T D Le Thi, S Colagiuri. Diabet Med 2009
M Marre, J Shaw, M Brändle, W M W Bebakar, N A Kamaruddin, J Strand, M Zdravkovic, T D Le Thi, S Colagiuri. Diabet Med 2009
5
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
D Russell-Jones, A Vaag, O Schmitz, B K Sethi, N Lalic, S Antic, M Zdravkovic, G M Ravn, R Simó. Diabetologia 2009
D Russell-Jones, A Vaag, O Schmitz, B K Sethi, N Lalic, S Antic, M Zdravkovic, G M Ravn, R Simó. Diabetologia 2009
5
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
David Russell-Jones, Robert M Cuddihy, Markolf Hanefeld, Ajay Kumar, Jose G González, Melanie Chan, Anne M Wolka, Marilyn K Boardman. Diabetes Care 2012
David Russell-Jones, Robert M Cuddihy, Markolf Hanefeld, Ajay Kumar, Jose G González, Melanie Chan, Anne M Wolka, Marilyn K Boardman. Diabetes Care 2012
5
Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).
Guillermo Umpierrez, Santiago Tofé Povedano, Federico Pérez Manghi, Linda Shurzinske, Valeria Pechtner. Diabetes Care 2014
Guillermo Umpierrez, Santiago Tofé Povedano, Federico Pérez Manghi, Linda Shurzinske, Valeria Pechtner. Diabetes Care 2014
5
ConoServer: updated content, knowledge, and discovery tools in the conopeptide database.
Quentin Kaas, Rilei Yu, Ai-Hua Jin, Sébastien Dutertre, David J Craik. Nucleic Acids Res 2012
Quentin Kaas, Rilei Yu, Ai-Hua Jin, Sébastien Dutertre, David J Craik. Nucleic Acids Res 2012
5
The engineering of an orally active conotoxin for the treatment of neuropathic pain.
Richard J Clark, Jonas Jensen, Simon T Nevin, Brid P Callaghan, David J Adams, David J Craik. Angew Chem Int Ed Engl 2010
Richard J Clark, Jonas Jensen, Simon T Nevin, Brid P Callaghan, David J Adams, David J Craik. Angew Chem Int Ed Engl 2010
5
Evolution of separate predation- and defence-evoked venoms in carnivorous cone snails.
Sébastien Dutertre, Ai-Hua Jin, Irina Vetter, Brett Hamilton, Kartik Sunagar, Vincent Lavergne, Valentin Dutertre, Bryan G Fry, Agostinho Antunes, Deon J Venter,[...]. Nat Commun 2014
Sébastien Dutertre, Ai-Hua Jin, Irina Vetter, Brett Hamilton, Kartik Sunagar, Vincent Lavergne, Valentin Dutertre, Bryan G Fry, Agostinho Antunes, Deon J Venter,[...]. Nat Commun 2014
5
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
Sten Madsbad. Diabetes Obes Metab 2016
Sten Madsbad. Diabetes Obes Metab 2016
5
The first venomous crustacean revealed by transcriptomics and functional morphology: remipede venom glands express a unique toxin cocktail dominated by enzymes and a neurotoxin.
Björn M von Reumont, Alexander Blanke, Sandy Richter, Fernando Alvarez, Christoph Bleidorn, Ronald A Jenner. Mol Biol Evol 2014
Björn M von Reumont, Alexander Blanke, Sandy Richter, Fernando Alvarez, Christoph Bleidorn, Ronald A Jenner. Mol Biol Evol 2014
8
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.